ResMed (ResMed) Common Stock

: $1 Mil (As of Dec. 2023)

View and export this data going back to 1995. Start your Free Trial

ResMed's quarterly common stock stayed the same from Jun. 2023 ($1 Mil) to Sep. 2023 ($1 Mil) and stayed the same from Sep. 2023 ($1 Mil) to Dec. 2023 ($1 Mil).

ResMed's annual common stock increased from Jun. 2021 ($1 Mil) to Jun. 2022 ($1 Mil) and increased from Jun. 2022 ($1 Mil) to Jun. 2023 ($1 Mil).

ResMed Common Stock Historical Data

The historical data trend for ResMed's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ResMed Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Common Stock

Get a 7-Day Free Trial

0.58

0.59

ResMed Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Common Stock	Get a 7-Day Free Trial															0.59	0.59	0.59	0.59	0.59

ResMed Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

ResMed (ResMed) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » ResMed Inc (NYSE:RMD) » Definitions » Common Stock

Comparable Companies

Traded in Other Exchanges

RSMDF:USA RMEA:Germany RME:Germany RMEA:Germany RME:Germany R1MD34:Brazil RMD:Australia

Address

9001 Spectrum Center Boulevard, San Diego, CA, USA, 92123

Website

https://www.resmed.com

ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.

Executives